All In Biotech

Drug Trial Radar · NCT04526665

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

161

Actual

Start

Sep 24, 2020

Primary completion

Jun 1, 2023

Study completion Dec 1, 2028

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Aug 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. The main aim of this study is to determine if elafibranor (the study drug) is better than placebo (a dummy treatment) at decreasing the levels of a specific blood test (alkaline phosphatase) that provides information about participant's disease. This study will also evaluate the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itchy skin (pruritus) and tiredness (fatigue). This study has two main parts: Part 1 will compare a daily dose of elafibranor to a daily dose of placebo and will last between a minimum of one year and a maximum of two years. Part 2, all participants will receive elafibranor for a period of up to 5 years or until the total treatment duration (part 1 and part 2) reaches 6 years, whichever occurs first.

Conditions

  • Primary Biliary Cirrhosis

Interventions

  • Elafibranor 80mgDrug

    Elafibranor 80mg daily

  • PlaceboDrug

    Placebo daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52Time frame: At Week 52

Locations

115 sites in 14 countries. Site status is shown where the registry gives one.

  • The Institute for Liver Health

    Chandler, Arizona

  • Keck Medical Center of USC

    Los Angeles, California

  • Ruane Clinical Research Group Inc.

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California, Davis Medical Center

    Sacramento, California

  • California Pacific Medical Center - Sutter Pacific Medical Foundation

    San Francisco, California

  • University of Colorado Denver and Hospital

    Aurora, Colorado

  • South Denver Gastroenterology, P.C.

    Englewood, Colorado

  • Yale School of Medicine, Digestive Diseases

    New Haven, Connecticut

  • Encore Borland-Groover Clinical Research

    Jacksonville, Florida

  • Schiff Center for Liver Diseases/University of Miami

    Miami, Florida

  • Digestive Healthcare of Georgia

    Atlanta, Georgia

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts

  • Henry Ford Health System

    Novi, Michigan

  • Saint Louis University

    St Louis, Missouri

  • UPMC Center for Liver Diseases

    New Hyde Park, New York

  • NYU Langone Health / NYU Grossman School of Medicine

    New York, New York

  • Columbia University Medical Center - Center for Liver Disease and Transplantation

    New York, New York

  • The New York-Presbyterian Hospital, David H. Koch Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Carolinas Centre for Liver disease/ Atrium Health

    Huntersville, North Carolina

  • Consultants for Clinical Research

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Investigational Drug Service Pharmacy Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina- College of Medicine

    Charleston, South Carolina

  • Vanderbilt Digestive Disease Center

    Nashville, Tennessee

  • Texas Clinical Research Institute, LLC

    Arlington, Texas

  • The Liver Institute at Methodist Dallas Medical Center

    Dallas, Texas

  • Liver Center of Texas, PLLC

    Dallas, Texas

  • The University of Texas Southwestern Medical Center-IDS Aston Pharmacy

    Dallas, Texas

  • Texas Digestive Disease Consultants dba GI Alliance

    Fort Worth, Texas

  • Liver Associates of Texas, P.A.

    Houston, Texas

  • St. Luke's Health-Baylor St Luke's Medical center - Advanced Liver Therapies Research

    Houston, Texas

  • American Research Corporation

    San Antonio, Texas

  • Gastro health & Nutrition-Victoria

    Victoria, Texas

  • Intermountain Medical Center - Transplant Services

    Murray, Utah

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.